Diabetes in Neuropsychiatric Disorders

Phase 1/2 Completed 30 enrolled National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

Non-randomizedSingle-groupOpen-labelTreatment

Summary

The purpose of this study was to describe metabolic changes in the first 16 weeks of anti-psychotic treatment in previously drug-naïve patients with psychosis. We hypothesize that in drug-naive patients, greater insulin resistance prior to treatment predicts a disproportionately greater increase in insulin resistance with olanzapine treatment.

Timeline

Start: 2006-04
Primary completion: 2010-03
Completion: 2010-03

Publications

Background Fernandez-Egea E, Miller B, Garcia-Rizo C, Bernardo M, Kirkpatrick B. Metabolic effects of olanzapine in patients with newly diagnosed psychosis. J Clin Psychopharmacol. 2011 Apr;31(2):154-9. doi: 10.1097/JCP.0b013e31820fcea3.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Olanzapine	Small molecule	10 mg	Oral
Subject	Olanzapine	Small molecule	15 mg	Oral
Subject	Olanzapine	Small molecule	40 mg	Oral

Diabetes in Neuropsychiatric Disorders

Summary

Timeline

Publications

Drugs

Indications